Biomarkers Resulting Detection For Cardiovascular Risk

Biomarkers resulting detection for cardiovascular risk in patients with juvenile onset systemic lupus erythematosus; by identifying ApoB:A1 ratio and metabolomic lipoprotein signatures as potential biomarkers in the body tests.

However, by unbiased hierarchical clustering stratified patients by metabolomic profile and revealing 3 distinct groups. Groups 1 and 2  were identifying as high and low cardiovascular risk respectively based on their unique lipoprotein profile, immune cell phenotype and clinical presentation; by identifying  ApoB:A1 ratio as a highly predictive bio marker distinguishing between these high and low cardiovascular risk groups.


But longitudinal analysis revealing that the ApoB:A1 ratio biomarker remaining stable overtime. As, ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile onset SLE.

But some patient stratification using these biomarkers could provide an opportunity for tailored disease treatments; using lipid modification therapy and lifestyle interventions; but group 1 are identifying as high cardiovascular risk due to their lipoprotein profile (decreased high density lipoproteins (HDL); and increased very low and low density lipoproteins (VLDL/LDL)).

Activating T-cells

So group 1 had a significant increase in plasma blasts and activating T-cells; comparing to matched healthy controls and had clinical features associated with increased disease activity; These immuno pathogenic properties were not seen in the low cardiovascular risk; Group Two which also had the opposite lipoprotein profile (increased HDL and decreased VLDL/LDL).

But group 2 had an intermediate CVR but a pro-inflammatory immune cell profile; research shows that SLE patients are between 9 and 50 fold more likely to suffer a myocardial infarction over the general population, and 3-fold more likely to suffer a fatal myocardial infarction.

The risk for certain types of deaths; primarily relating to lupus activity has decreasing over time; while the risk for deaths due to circulatory disease does not appear to have diminishing.35 JSLE patients and 39 age/sex matched healthy donors. Metabolic bio marker analysis and in depth immune cell pheno typing is performing on the serum and peripheral blood mononuclear cells ;(PBMCs) taking from the participants.